Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Dermatitis symbols : ABBV save search
Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published: 2024-04-08 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.24%
H: 0.0%
C: -0.8%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -3.43%
H: 6.21%
C: 6.21%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.25%
H: 1.1%
C: -0.17%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.05%
H: 0.43%
C: -0.27%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.08%
H: 0.04%
C: -0.35%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -7.27%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.77%
H: 1.63%
C: 0.35%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.18%
H: 0.3%
C: 0.19%
eczema dermatitis set therapeutics market
Atopic Dermatitis Drugs Market to grow by USD 4.7 billion from 2022-2027 | North America to account for 36% of market growth- Technavio
Published: 2023-10-17 (Crawled : 05:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.27%
H: 1.38%
C: 0.83%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.95%
H: 1.81%
C: 0.53%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.2%
H: 0.44%
C: -0.56%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.4%
H: 0.0%
C: 0.0%
PHGE | $0.2852 -3.58% 3.16% 69K
|
Health Technology
|
| O: 5.0%
H: 3.17%
C: -1.56%
america dermatitis market
AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
abbvie dermatitis rinvoq
Dermatitis Global Market Research Report 2023: An $8.57 Billion Market by 2027 - Long-term Forecasts to 2032
Published: 2023-03-20 (Crawled : 11:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: -0.06%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.98%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.5%
H: 1.38%
C: 1.23%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.78%
H: 0.74%
C: 0.72%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 1.38%
H: 1.16%
C: 1.13%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.19%
H: 1.18%
C: 1.04%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
report dermatitis research global market
U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis
Published: 2022-01-14 (Crawled : 19:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
rinvoq fda atopic dermatitis dermatitis children order
AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress
Published: 2021-09-30 (Crawled : 19:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.33%
H: 1.12%
C: -1.22%
dermatitis atopic dermatitis
European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Published: 2021-08-24 (Crawled : 14:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: -0.03%
treatment europe dermatitis atopic dermatitis
Global Atopic Dermatitis Drugs Market Report 2021: Rising Incident of Food Allergies Intensifying Atopic Dermatitis - Forecast to 2026
Published: 2021-08-19 (Crawled : 23:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.56%
H: 0.87%
C: 0.7%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.17%
H: 0.67%
C: 0.26%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 0.04%
H: 1.71%
C: 0.18%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.14%
H: 1.16%
C: 0.61%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
food dermatitis drug atopic dermatitis
JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
Published: 2021-08-04 (Crawled : 19:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.4%
H: 0.64%
C: -0.6%
dermatitis phase 3 atopic dermatitis dupixent
AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.
Published: 2021-07-16 (Crawled : 14:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.62%
H: 0.36%
C: -0.35%
treatment dermatitis atopic dermatitis
CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis
Published: 2021-06-25 (Crawled : 07:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.6%
H: 0.61%
C: 0.07%
treatment dermatitis approval chmp atopic dermatitis
The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis
Published: 2021-05-24 (Crawled : 13:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.4%
H: 0.19%
C: -0.58%
results dermatitis phase 3 atopic dermatitis lancet
AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis
Published: 2021-04-02 (Crawled : 22:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
new drug treatment dermatitis drug atopic dermatitis
RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
Published: 2020-12-10 (Crawled : 14:12) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.36%
H: 0.01%
C: -1.44%
dermatitis phase 3 atopic dermatitis dupixent
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.